Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Zentrale

Gunther R Adolf

Peter Swetly

Rudolf Hauptmann

Gerhard Bodo

Norbert Hauel

Ingrid Maurer-Fogy

Adolf Himmler

Peter Meindl

Erik Patzelt

Edgar Falkner

Walter Spevak

Karl-Heinz Heider

Christian Stratowa

Elinborg Ostermann

Christiaan Maria Reutelingsperger

John James Miglietta

Augustinus Antonius Maria Silvester Van Dongen

Marlies Sproll

Maria J Castanon

Ewa Chlebowicz-Sledziewska

Andrzej Sledziewski

Silvia J Lindner-Frimmel

Hans Tuppy

The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.

Antibodies specific for CD44v6

Monoclonal antibody against CD44v6

This invention relates to biologically active proteins, the DNA molecules coding for them, processes for preparing them and their use.

Vascular anticoagulant proteins DNA which codes them, processer for

This invention relates to a process for preparing recombinant horse and dog interferons and the interferons themselves.

Recombinant production of dog and horse type I interferons

This invention relates to a process for preparing human lysozyme and the human lysozyme protein itself.

Human lysozyme

Recombinant dog and horse type I interferons

The invention relates to new monoclonal antibodies which react specifically with human interferon of the IFN-omega type but not with other human interferons, and processes for preparing them, and for methods for their use in the purification and detection of IFN-omega.

Monoclonal antibodies against IFN-omega, processes for preparing them

This invention relates to new hybrid interferons consisting of part of an .alpha.-interferon and part of an omega interferon, the N-terminal Met or N-formyl-Met derivatives thereof and, if the peptide sequence of the hybrid interferon contains a glycosylation site, the N-glycosylated derivatives thereof, their use as pharmaceutical compositions and as intermediate products for immunizing experimental animals and processes for producing them,

Hybrid interferons, their use as pharmaceutical compositions and as

Ternary compositions of an interferon of the alpha and/or beta type with an interferon of the gamma type and tumor necrosis factor having a surprising and unexpected synergistic anti-proliferative effect on neoplastic cells when compared to the activity of the individual components of this invention, said compositions being useful in the treatment of neoplasia in animals including humans.

Synergistic mixtures of interferons and tumor necrosis factor

This invention is directed to a process of producing interferon which comprises incubating permanent cell lines of lymphoblast origin or human fibroblast cells with interferon inducers and stimulator substances and recovering the interferon produced.

Process for the production of human interferon

Growing community of inventors

Vienna, Austria

Gunther R Adolf